Altimmune Shares Fall After Q4 Results

MT Newswires Live

11 hours ago

Altimmune (ALT) shares were down about 12% in Thursday trading after the clinical-stage drugmaker reported a wider-than-expected Q4 loss.

Earlier, the company posted a Q4 net loss of $0.27 per diluted share, narrower than a loss of $0.33 a year earlier. Analysts expected a loss of $0.23 in a FactSet poll.

Looking ahead, Altimmune said it has a number of inflection points in 2026, including the upcoming initiation of a phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis.

The company said it is actively finalizing the study plan.

The firm also said it is expecting topline data from its phase 2 trial of pemvidutide in alcohol use disorder in Q3.

Price: 3.76, Change: -0.52, Percent Change: -12.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2617578672"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617578672\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617578672?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 03:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617578672","market":"us","top_or_hot":-1,"title":"Altimmune Shares Fall After Q4 Results","media":"MT Newswires Live","content":"<html><body><p> Altimmune (ALT) shares were down about 12% in Thursday trading after the clinical-stage drugmaker reported a wider-than-expected Q4 loss.</p><p>Earlier, the company posted a Q4 net loss of $0.27 per diluted share, narrower than a loss of $0.33 a year earlier. Analysts expected a loss of $0.23 in a FactSet poll.</p><p>Looking ahead, Altimmune said it has a number of inflection points in 2026, including the upcoming initiation of a phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis.</p><p>The company said it is actively finalizing the study plan.</p><p>The firm also said it is expecting topline data from its phase 2 trial of pemvidutide in alcohol use disorder in Q3.</p><p>Price: 3.76, Change: -0.52, Percent Change: -12.06</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Shares Fall After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Shares Fall After Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-06 03:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Altimmune (ALT) shares were down about 12% in Thursday trading after the clinical-stage drugmaker reported a wider-than-expected Q4 loss.</p><p>Earlier, the company posted a Q4 net loss of $0.27 per diluted share, narrower than a loss of $0.33 a year earlier. Analysts expected a loss of $0.23 in a FactSet poll.</p><p>Looking ahead, Altimmune said it has a number of inflection points in 2026, including the upcoming initiation of a phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis.</p><p>The company said it is actively finalizing the study plan.</p><p>The firm also said it is expecting topline data from its phase 2 trial of pemvidutide in alcohol use disorder in Q3.</p><p>Price: 3.76, Change: -0.52, Percent Change: -12.06</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617578672","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617578672","pubTimestamp":1772737873,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Altimmune (ALT) shares were down about 12% in Thursday trading after the clinical-stage drugmaker reported a wider-than-expected Q4 loss.Earlier, the company posted a Q4 net loss of $0.27 per diluted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","BK4139":"生物科技","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","ALT":"Altimmune, Inc."},"translate_title":"Altimmune股价在第四季度业绩公布后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":1},"content_text":"Altimmune (ALT) shares were down about 12% in Thursday trading after the clinical-stage drugmaker reported a wider-than-expected Q4 loss.Earlier, the company posted a Q4 net loss of $0.27 per diluted share, narrower than a loss of $0.33 a year earlier. Analysts expected a loss of $0.23 in a FactSet poll.Looking ahead, Altimmune said it has a number of inflection points in 2026, including the upcoming initiation of a phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis.The company said it is actively finalizing the study plan.The firm also said it is expecting topline data from its phase 2 trial of pemvidutide in alcohol use disorder in Q3.Price: 3.76, Change: -0.52, Percent Change: -12.06","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}